Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.
Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.
复制标题
通过磁共振成像/超声融合活检确定的焦点治疗资格。
DOI：
10.1016/j.juro.2017.08.085
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Natarajan S
中科院分区：
文献类型：
--
作者：
Nassiri N;Chang E;Lieu P;Priester AM;Margolis DJA;Huang J;Reiter RE;Dorey FJ;Marks LS;Natarajan S
在接受多参数磁共振成像（mpMRI）和靶向活检的男性中评估病灶治疗（FT）的合格性，并与根治性乳腺癌切除术（RP）后的整体组织学相关。受试者选自454名男性（2010-2016年），这些男性患有靶向活检证实的前列腺癌（CaP），这些前列腺癌来自mpMRI上的感兴趣区域（ROI）。FT资格限制为在有或没有其他低风险CaP病灶（GS 3+3，< 4 mm）的ROI内最大格里森评分（GS）为4+3。不符合NCCN中等风险标准的男性被归类为不适合FT。454名男性中的64名接受RP，并将活检结果与最终病理学进行比较。38.5%（175/454）活检证实ROI的男性有资格接受FT。融合活检结合靶向活检和模板活检，对于FT合格性的敏感性、特异性和准确性分别为80.0%（12/15）、73.5%（36/49）和75.0%（48/64）。单独靶向核心的敏感性为73.3%（11/15），特异性为47.9%（23/48），准确性为54.7%（35/64）。活检和整体包埋组织学之间的不一致病例在GS（4/13）和中线延伸（9/13）方面不同。使用中等风险的合格标准，超过三分之一的男性在mpMRI上发现了靶向活检证实的病变，有资格接受FT。融合活检确定的合格性与75%的病例的整体组织学一致。需要改进选择标准，以可靠地确定金融服务的资格。
To assess focal therapy (FT) eligibility among men receiving multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy, with correlation to whole mount histology after radical prostatectomy (RP). Subjects were selected from among the 454 men (2010–2016) with targeted biopsy-proven prostate cancer (CaP) derived from regions of interest (ROI) on mpMRI. FT eligibility was limited to a maximum Gleason score (GS) of 4+3 within ROIs with or without other foci of low-risk CaP (GS 3+3, < 4 mm). Men who did not meet NCCN intermediate risk criteria were classified as ineligible for FT. 64 of the 454 men received RP, and biopsy findings were compared to final pathology. 38.5% (175/454) of men with a biopsy-proven ROI were eligible for FT. Fusion biopsy, which combined both targeted and template biopsy, had a sensitivity, specificity, and accuracy of 80.0% (12/15), 73.5% (36/49), and 75.0% (48/64) respectively for FT eligibility. Targeted cores alone yielded a sensitivity of 73.3% (11/15), a specificity of 47.9% (23/48), and an accuracy of 54.7% (35/64). Discordant cases between biopsy and whole mount histologies differed in GS (4/13) and extension across the midline (9/13). Using intermediate-risk eligibility criteria, more than one-third of men with a targeted biopsy-proven lesion identified on mpMRI would have been eligible for FT. Eligibility determined by fusion biopsy was concordant with whole mount histology in 75% of cases. Improved selection criteria are needed to reliably determine FT eligibility.
登录
查看更多内容
影响因子：
3
作者：
Marshall S;Taneja S
通讯作者：
Taneja S
DOI：
10.1097/pas.0b013e3182556dcd
发表时间：
2012-09
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Ross HM;Kryvenko ON;Cowan JE;Simko JP;Wheeler TM;Epstein JI
通讯作者：
Epstein JI
MR/超声融合引导的活检与超声引导活检的比较，以诊断前列腺癌。
DOI：
10.1001/jama.2014.17942
发表时间：
2015-01-27
期刊：
JAMA
影响因子：
--
作者：
Siddiqui MM;Rais-Bahrami S;Turkbey B;George AK;Rothwax J;Shakir N;Okoro C;Raskolnikov D;Parnes HL;Linehan WM;Merino MJ;Simon RM;Choyke PL;Wood BJ;Pinto PA
通讯作者：
Pinto PA
DOI：
10.1016/j.urolonc.2011.02.014
发表时间：
2011-05
期刊：
Urologic oncology
影响因子：
--
作者：
Natarajan S;Marks LS;Margolis DJ;Huang J;Macairan ML;Lieu P;Fenster A
通讯作者：
Fenster A
影响因子：
23.4
作者：
Ahmed, Hashim U.;Dickinson, Louise;Emberton, Mark
通讯作者：
Emberton, Mark